What is the recommended starting dose, titration schedule, contraindications, and monitoring for escitalopram in adults with major depressive disorder or generalized anxiety disorder?

Escitalopram for Major Depressive Disorder and Generalized Anxiety Disorder

Start escitalopram at 10 mg once daily (morning or evening, with or without food) for both major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults. 1

Starting Dose and Titration

Adults

• Initial dose: 10 mg once daily for both MDD and GAD 1
• Titration to 20 mg: Wait minimum 1 week for adults with MDD or GAD before increasing 1
• Note: Fixed-dose trials showed 10 mg and 20 mg both effective for MDD, but 20 mg did not demonstrate greater benefit over 10 mg 1

Adolescents (MDD only)

• Initial dose: 10 mg once daily 1
• Titration to 20 mg: Wait minimum 3 weeks before increasing 1

Special Populations

• Elderly patients: 10 mg/day maximum (do not increase) 1
• Hepatic impairment: 10 mg/day maximum 1
• Renal impairment: No adjustment needed for mild-moderate; use caution in severe renal impairment 1

Absolute Contraindications

Do not use escitalopram with:

• MAOIs (phenelzine, isocarboxazid, moclobemide, isoniazid, linezolid): Risk of fatal serotonin syndrome 2, 1
• Wait 14 days after stopping MAOI before starting escitalopram 1
• Wait 14 days after stopping escitalopram before starting MAOI 1

Critical Monitoring Requirements

Initial Phase (First 1-2 Months)

Monitor closely for suicidal ideation and behavior, especially in the first 1-2 weeks 3

• SSRIs carry increased risk for suicide attempts compared to placebo 3
• Assess for agitation, irritability, unusual behavioral changes 3
• Risk for suicide attempts is greatest during first 1-2 months of treatment 3

Cardiac Monitoring

Screen for QT prolongation risk factors before initiating 2, 4:

• Escitalopram (and citalopram) can prolong QT interval 2, 4
• Avoid in patients with long QT syndrome 2
• Use caution with drugs that prolong QT interval 2
• FDA/EMA have limited maximum doses due to QT concerns 4
• For patients >60 years, maximum dose further reduced 4

Ongoing Assessment

• Evaluate therapeutic response within 6-8 weeks 3
• If inadequate response after 6-8 weeks at therapeutic dose, modify treatment 3
• Response rate to antidepressants may be as low as 50% 3

Drug Interactions

Lower Risk Profile

Escitalopram has the least effect on CYP450 enzymes compared to other SSRIs, resulting in lower propensity for drug interactions 2

Use Caution With:

• Other serotonergic drugs: SSRIs, SNRIs, TCAs, tramadol, meperidine, methadone, fentanyl, amphetamines, dextromethorphan, St. John's wort, L-tryptophan 2
• Start second serotonergic drug at low dose, increase slowly, monitor for serotonin syndrome especially in first 24-48 hours after dose changes 2
• QT-prolonging medications 2, 4

Serotonin Syndrome Warning Signs

Monitor for: confusion, agitation, anxiety, tremors, clonus, hyperreflexia, muscle rigidity, hypertension, tachycardia, diaphoresis, fever, seizures 2

• Can be fatal; requires immediate hospitalization and discontinuation of all serotonergic agents 2

Treatment Duration

Acute Phase

• Continue for 4-9 months after satisfactory response for first episode of MDD 3
• Longer duration beneficial for patients with ≥2 episodes of depression 3
• Maintenance treatment demonstrated benefit in preventing relapse 1

Discontinuation

Taper gradually rather than abrupt cessation 1:

• Discontinuation syndrome can occur (dizziness, fatigue, headaches, nausea, insomnia, paresthesias, anxiety, irritability) 2
• Escitalopram has shorter half-life; discontinuation symptoms possible but less severe than paroxetine 2
• If intolerable symptoms occur during taper, resume previous dose and decrease more gradually 1

Common Adverse Effects

Most common (≥5% and twice placebo rate): 1

• Nausea (15% vs 7% placebo) - typically mild and transient
• Insomnia (9% vs 4%)
• Ejaculation disorder/delay (9% vs <1% in males)
• Fatigue (5% vs 2%)
• Increased sweating (5% vs 2%)
• Somnolence (6% vs 2%)

Management tip: Starting with subtherapeutic "test" dose may reduce initial anxiety/agitation that can occur with SSRIs 2

Pre-Treatment Screening

Screen for bipolar disorder before initiating 1:

• Assess personal and family history of bipolar disorder, mania, or hypomania
• Antidepressants can precipitate manic episodes in bipolar disorder

Efficacy Evidence

Escitalopram demonstrates efficacy at half the dose of racemic citalopram 5, 6:

• Symptom improvement can occur within 1-2 weeks 5
• Earlier separation from placebo compared to citalopram 5
• Response rates: 58-68% for MDD, 75-81% for GAD 7, 8
• Remission rates: 73-82% for MDD, 76% for GAD in long-term studies 9, 10, 11